Entresto's Theoretical Alzheimer's Risk Draws Practical FDA Response
Executive Summary
FDA's authority to require post-marketing studies can extend to theoretical risks, even in absence of clinical evidence, office director Unger concluded when he overrode review team's more informal consensus with Novartis about how to address hypothetical risk of Alzheimer's from the heart failure drug; see our November Drug Review Profile.
You may also be interested in...
Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116
As Merck’s 21-valent vaccine approaches its 17 June user fee goal, the US CDC’s vaccine committee is looking at new adult age-based recommendations and bracing for a full pipeline led by GSK’s 24-valent candidate.
US FDA Expects Joint AdComm Briefing Document, Oncology Chief Says
The combined format is the new default for briefing advisory committee members, US FDA Oncology Center of Excellence Director Pazdur declared.
Minimal Residual Disease Gains Max US FDA AdComm Support For Myeloma Trials
The US FDA’s Oncologic Drugs Advisory Committee unanimously agreed that accelerated approvals should be enabled by multiple myeloma trials using MRD as a surrogate endpoint.